Non-Small Cell Lung Cancer Coverage from Every Angle
Advertisement
Advertisement

Recent News

JAVELIN Medley VEGF: Monoclonal Antibody Plus VEGFR Inhibitor Studied in NSCLC
FDA Brief: Zenocutuzumab Granted Fast Track Designation for NRG1 Fusion Cancers
Biomarker May Predict Susceptibility to Radiation Pneumonitis in Patients With Lung Cancer
Tiragolumab Combination Treatment Granted Breakthrough Therapy Designation in NSCLC
Can Chemoimmunotherapy Achieve Pathologic Downstaging in Resectable Lung Cancer?
Lorlatinib Receives Priority Review in Untreated ALK-Positive Lung Cancer
Adjuvant Osimertinib Approved by FDA for EGFR-Mutated Lung Cancer
Individualized Versus Standard Dosing of Radiotherapy in Stage III NSCLC
Stereotactic Body Radiotherapy for Larger Lung Tumors
First-Line Pembrolizumab Plus Niraparib in Advanced Metastatic NSCLC
Ramucirumab Plus Osimertinib in NSCLC: Final Analysis of Phase I Trial
Novel Immune Checkpoint Inhibitor Under Study in Advanced NSCLC
Targeting KRAS Mutations in Advanced NSCLC: Early Trial Results
Capmatinib in MET-Dysregulated Advanced NSCLC: GEOMETRY Mono-1
ESMO Asia 2020: Adding PD-L1 Inhibitor to Platinum-Based Chemotherapy for NSCLC
Lorlatinib for First-Line Treatment of ALK-Positive NSCLC
SITC 2020: Bemcentinib and Pembrolizumab in Stage IV Lung Adenocarcinoma
SITC 2020: Vactosertib Plus Durvalumab in PD-L1–Positive NSCLC
ASTRO 2020: Pericardial Effusion and Survival With Radiation Therapies in Locally Advanced NSCLC
Timing of Brain Radiotherapy for NSCLC With Brain Metastasis
ASTRO 2020: Stereotactic Body Radiotherapy With and Without Pembrolizumab Under Study in Lung Cancer
Equivalence Study of Bevacizumab Biosimilar in Metastatic Nonsquamous NSCLC
ASTRO 2020: Cardiac Events With Photon Versus Proton Radiotherapy for Lung Cancer
Lung Cancer and Severity of COVID-19: Experience From MSK
Osimertinib Receives Priority Review for EGFR-Mutant NSCLC
Early Clinical Data on Sotorasib in Advanced NSCLC
Treatment Duration for Nivolumab in Advanced NSCLC: CheckMate 153
ESMO 2020: Does Immune Oncology Increase the Risk of SARS-CoV2–Related Mortality in NSCLC?
ESMO 2020: Pembrolizumab Versus Docetaxel in Subgroup of Patients With NSCLC
ESMO 2020: Vinorelbine Plus Atezolizumab in Recurrent Stage IV Lung Cancer
ESMO 2020: First-Line Pembrolizumab, Chemotherapy, and Lenvatinib in Metastatic NSCLC
Study Supports Use of RET Inhibitor in RET Fusion–Positive Lung Cancer
ESMO 2020: CNS Recurrence Patterns With Osimertinib in Treatment of NSCLC
ESMO 2020: Is Neoadjuvant Atezolizumab Safe in Patients With Resectable NSCLC?
ESMO 2020: Combining Ipilimumab With PD-1 Blockade in Advanced Lung Cancer
ESMO 2020: Lorlatinib Versus Crizotinib in First-Line Treatment of ALK-Positive NSCLC
ESMO 2020: Is Routine Postoperative Radiotherapy in NSCLC With Mediastinal Nodes of Benefit?
COVID-19 and Lung Cancer: Skin Manifestations With Immunotherapy
Are ‘Light’ Smokers at Increased Risk of Death From Lung Cancer?
FDA Brief: Pemetrexed Injection Receives FDA Approval for Lung Cancer
Pralsetinib Approved by FDA for Metastatic RET Fusion–Positive NSCLC
Survival Outcomes in Lung Cancer in the United Kingdom During the COVID-19 Pandemic
COVID-19 and Thoracic Cancer: First Results From TERAVOLT
Liquid Biopsy Companion Diagnostic Test Approved for Metastatic NSCLC
Lung Cancer and COVID-19: Global Experts Offer Treatment Guidance
Does Nicotine Promote Brain Metastasis of Lung Cancer?
FDA Grants Priority Review for New Durvalumab Dosing Regimen in NSCLC
AACR COVID-19: SRMS Expression in Patients With Lung Cancer
WCLC 2020: Ensartinib Versus Crizotinib in First-Line Treatment of ALK-Positive NSCLC
AACR COVID-19: Changes in Lung Cancer Management
WCLC 2020: Adding Sintilimab to Chemotherapy for Nonsquamous NSCLC
Phase I Trial of Combined MEK and EGFR Inhibition in NSCLC
COVID-19 and Lung Cancer: Proactive Measures for Screening Patients
Osimertinib Given Breakthrough Therapy Designation for EGFR-Mutated Lung Cancer
ctDNA Clearance and Savolitinib Plus Osimertinib in MET-Amplified Lung Cancer
Survival Update With Bevacizumab Plus Erlotinib in Certain Patients With NSCLC


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.